Dishman Carbogen Amcis Limited
NSE: DCAL BSE: DCAL
Prev Close
210.31
Open Price
210.8
Volume
169,506
Today Low / High
207.72 / 211.5
52 WK Low / High
133 / 307.98
Range
200 - 221
Prev Close
210.2
Open Price
207.1
Volume
13,519
Today Low / High
207.1 / 211.7
52 WK Low / High
132.75 / 307.8
Range
200 - 221
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 210.73 (target range: 200 - 221), reflecting a change of 0.42 (0.19971%). On the BSE, it is listed at 210.75 (target range: 200 - 221), showing a change of 0.55 (0.26166%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Dishman Carbogen Amcis Limited Graph
Dishman Carbogen Amcis Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Dishman Carbogen Amcis Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 210.73, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 210.75 | 212.86 | 191.57 - 234.14 |
| 214.97 | 171.97 - 257.96 | ||
| 217.07 | 151.95 - 282.19 | ||
| Bearish Scenario | 210.75 | 208.64 | 187.78 - 229.51 |
| 206.54 | 165.23 - 247.84 | ||
| 204.43 | 143.10 - 265.76 |
Overview of Dishman Carbogen Amcis Limited
ISIN
INE385W01011
Industry
Biotechnology
Vol.Avg
381,150
Market Cap
33,038,902,663
Last Dividend
0
Official Website
IPO Date
2004-04-22
DCF Diff
348.21
DCF
-138
Financial Ratios Every Investor Needs
Stock Dividend of DCAL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2019-09-12 | September 12, 19 | 0.2 | 0.2 | 2019-09-13 | 2019-10-24 | 2019-05-15 |
| 2017-02-17 | February 17, 17 | 1.2 | 1.2 | 2017-02-21 | 2017-03-01 | |
| 2016-03-17 | March 17, 16 | 1 | 2 | |||
| 2015-09-10 | September 10, 15 | 1 | 2 | |||
| 2014-08-21 | August 21, 14 | 0.6 | 1.2 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 2,543.62 Cr | 2,401.76 Cr | 141.86 Cr | 0.0558 | 12.98 Cr | 133.06 Cr | -47.86 Cr | -153.45 Cr | -9.79 | 307.18 Cr | -0.0603 |
| 2023-03-31 | 2,315.05 Cr | 534.21 Cr | 1,780.84 Cr | 0.7692 | 0.00 Cr | 100.34 Cr | 105.49 Cr | -29.80 Cr | -1.90 | 307.62 Cr | -0.0129 |
| 2022-03-31 | 2,140.68 Cr | 458.88 Cr | 1,681.80 Cr | 0.7856 | 13.90 Cr | 72.16 Cr | 29.85 Cr | 18.01 Cr | 1.15 | 342.56 Cr | 0.0084 |
| 2021-03-31 | 1,912.03 Cr | 484.09 Cr | 1,427.94 Cr | 0.7468 | 6.50 Cr | 63.09 Cr | -12.35 Cr | -165.13 Cr | -10.53 | 286.42 Cr | -0.0864 |
| 2020-03-31 | 2,043.60 Cr | 1,667.83 Cr | 375.77 Cr | 0.1839 | 21.55 Cr | 55.76 Cr | 233.13 Cr | 158.51 Cr | 9.85 | 524.93 Cr | 0.0776 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 264.09 Cr | 9,581.41 Cr | 3,953.91 Cr | 5,627.5000 Cr | 2,312.60 Cr | 2,048.51 Cr | 882.89 Cr | 3,236.14 Cr | 0.00 Cr | 0.00 Cr | -88.50 Cr | 2,554.7200 Cr |
| 2023-03-31 | 131.79 Cr | 9,453.50 Cr | 3,643.83 Cr | 5,809.6700 Cr | 2,208.85 Cr | 2,077.06 Cr | 803.80 Cr | 3,234.70 Cr | 429.65 Cr | 165.12 Cr | -131.56 Cr | 1,798.3900 Cr |
| 2022-03-31 | 110.24 Cr | 8,637.45 Cr | 3,088.51 Cr | 5,548.9400 Cr | 1,829.89 Cr | 1,719.65 Cr | 645.12 Cr | 2,786.88 Cr | 294.58 Cr | 126.50 Cr | 31.83 Cr | 1,419.7900 Cr |
| 2021-03-31 | 243.54 Cr | 8,366.10 Cr | 2,667.28 Cr | 5,698.8200 Cr | 1,588.85 Cr | 1,345.31 Cr | 515.65 Cr | 2,441.46 Cr | 0.00 Cr | -0.01 Cr | 55.78 Cr | 1,290.2900 Cr |
| 2020-03-31 | 121.94 Cr | 8,199.81 Cr | 2,484.75 Cr | 5,715.9000 Cr | 1,357.44 Cr | 1,235.50 Cr | 580.87 Cr | 2,092.98 Cr | 200.39 Cr | 0.00 Cr | 88.87 Cr | 1,568.9500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 383.9700 Cr | -229.5200 Cr | -22.1500 Cr | 80.7200 Cr | 132.3000 Cr | 264.0900 Cr | -303.2500 Cr | -153.4500 Cr | 119.2600 Cr | 0.0000 Cr | -85.2400 Cr |
| 2023-03-31 | 265.9500 Cr | -494.0800 Cr | 249.6700 Cr | -353.7300 Cr | 21.5500 Cr | 131.7900 Cr | -619.6800 Cr | -54.5900 Cr | 134.5500 Cr | 0.0000 Cr | -158.6800 Cr |
| 2022-03-31 | 354.8500 Cr | -618.5300 Cr | 130.3700 Cr | -108.9500 Cr | -133.3000 Cr | 110.2400 Cr | -463.8000 Cr | -4.2500 Cr | 216.8200 Cr | 0.0000 Cr | -143.3000 Cr |
| 2021-03-31 | 512.6600 Cr | -380.7900 Cr | -11.0400 Cr | 146.6300 Cr | 121.6000 Cr | 243.5400 Cr | -366.0300 Cr | -65.0300 Cr | 102.4600 Cr | 0.0000 Cr | 90.9100 Cr |
| 2020-03-31 | 585.1400 Cr | -441.7400 Cr | -97.7700 Cr | 176.5800 Cr | 45.6200 Cr | 121.9400 Cr | -408.5600 Cr | 197.2000 Cr | 3.2400 Cr | -3.2300 Cr | -58.2500 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 682.34 Cr | 98.83 Cr | 583.51 Cr | 0.8552 | 68.16 Cr | 4.63 Cr | 0.30 | 147.80 Cr | 0.0068 |
| 2024-09-30 | 789.04 Cr | 190.56 Cr | 598.48 Cr | 0.7585 | 75.06 Cr | 33.09 Cr | 2.11 | 150.84 Cr | 0.0419 |
| 2024-06-30 | 523.78 Cr | 454.18 Cr | 69.60 Cr | 0.1329 | -41.62 Cr | -77.57 Cr | -4.95 | 24.96 Cr | -0.1481 |
| 2024-03-31 | 654.71 Cr | 587.91 Cr | 66.80 Cr | 0.1020 | -22.32 Cr | -69.92 Cr | -4.46 | 66.75 Cr | -0.1068 |
| 2023-12-31 | 651.09 Cr | 509.15 Cr | 141.94 Cr | 0.2180 | 37.11 Cr | -59.63 Cr | -3.80 | 47.16 Cr | -0.0916 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 228.40 Cr | 202.09 Cr | 430.49 Cr | 0.00 Cr | 903.90 Cr | 2,144.44 Cr | 3,320.22 Cr | 10,180.45 Cr | 4,443.69 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 436.64 Cr | 0.00 Cr | 0.00 Cr | 436.64 Cr | 0.00 Cr | 0.00 Cr | -5,627.50 Cr |
| 2024-03-31 | 264.09 Cr | 167.35 Cr | 431.44 Cr | 461.11 Cr | 882.89 Cr | 1,928.19 Cr | 3,236.14 Cr | 9,581.41 Cr | 3,953.91 Cr |
| 2023-12-31 | -472.94 Cr | 945.88 Cr | 472.94 Cr | 0.00 Cr | 0.00 Cr | 472.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 187.44 Cr | 297.13 Cr | 484.57 Cr | 472.02 Cr | 851.69 Cr | 1,963.11 Cr | 3,239.79 Cr | 9,501.12 Cr | 3,730.29 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | -77.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -69.92 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -59.63 Cr | 160.74 Cr | 0.00 Cr | 0.00 Cr | 160.74 Cr | 557.74 Cr | 397.00 Cr | 0.00 Cr | 160.74 Cr |
| 2023-09-30 | -40.90 Cr | 150.08 Cr | 0.00 Cr | 0.00 Cr | 150.08 Cr | 397.00 Cr | 246.92 Cr | 0.00 Cr | 150.08 Cr |
| 2023-06-30 | 17.00 Cr | 140.90 Cr | 0.00 Cr | 0.00 Cr | 140.90 Cr | 334.24 Cr | 193.34 Cr | 0.00 Cr | 140.90 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2016-05-02 | May 02, 16 | 2:1 |
| 2005-10-21 | October 21, 05 | 5:1 |
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹331.90 | ₹398,479,140,000.00 | ₹1,860,996.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹220.76 | ₹292,672,172,632.00 | ₹3,206,567.00 |
| Syngene International Limited | SYNGENE | ₹724.60 | ₹290,777,127,354.00 | ₹309,960.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,712.30 | ₹179,134,319,260.00 | ₹167,947.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹742.40 | ₹128,780,727,808.00 | ₹402,801.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹674.95 | ₹107,506,805,443.00 | ₹165,388.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹743.80 | ₹59,863,106,640.00 | ₹485,094.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹210.73 | ₹33,038,902,663.00 | ₹169,506.00 |
| Panacea Biotec Limited | PANACEABIO | ₹504.80 | ₹30,919,375,571.00 | ₹556,110.00 |
| Zota Health Care Limited | ZOTA | ₹884.35 | ₹24,657,917,174.00 | ₹61,116.00 |
Key Executives
Gender: male
Year Born:
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: female
Year Born: 1951
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1986
FAQs about Dishman Carbogen Amcis Limited
The CEO is Mr. Pascal Villemagne.
The current price is ₹210.73.
The range is ₹133-307.98.
The market capitalization is ₹3,303.89 crores.
The P/E ratio is -29.63.
The company operates in the Healthcare sector.
Overview of Dishman Carbogen Amcis Limited (ISIN: INE385W01011) is a leading Biotechnology in India. With a market capitalization of ₹3,303.89 crores and an average daily volume of 381,150 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.